Designed to target skin cancer, the implantable vaccine opens a door to treating many cancers and inflammatory diseases
A cross-disciplinary team of scientists, engineers, and clinicians announced today that they have begun a Phase I clinical trial of an implantable vaccine to treat melanoma, the most lethal form of skin cancer.
The effort is the fruit of a new model of translational research being pursued at the Wyss Institute for Biologically Inspired Engineering at Harvard University that integrates the latest cancer research with bioinspired technology development. It was led by Wyss Core Faculty member David J. Mooney, Ph.D., who is also the Robert P. Pinkas Family Professor of Bioengineering at the Harvard School of Engineering and Applied Sciences (SEAS), and Wyss Institute Associate Faculty member Glenn Dranoff, M.D., who is co-leader of Dana-Farber Cancer Institute’s Cancer Vaccine Center.
Most therapeutic cancer vaccines available today require doctors to first remove the patient’s immune cells from the body, then reprogram them and reintroduce them back into the body. The new approach, which was first reported to eliminate tumors in mice in Science Translational Medicine in 2009, the year the Wyss Institute was launched, instead uses a small disk-like sponge about the size of a fingernail that is made from FDA-approved polymers. The sponge is implanted under the skin, and is designed to recruit and reprogram a patient’s own immune cells “on site,” instructing them to travel through the body, home in on cancer cells, then kill them.
The technology was initially designed to target cancerous melanoma in skin, but might have application to other cancers. In the preclinical study reported in Science Translational Medicine, 50 percent of mice treated with two doses of the vaccine — mice that would have otherwise died from melanoma within about 25 days — showed complete tumor regression.
“Our vaccine was made possible by combining a wide range of biomedical expertise that thrives in Boston and Cambridge,” said Mooney, who specializes in the design of biomaterials for tissue engineering and drug delivery. “It reflects the bioinspired engineering savvy and technology development focus of engineers and scientists at the Wyss Institute and Harvard SEAS, as well as the immunological and clinical expertise of the researchers and clinicians at Dana-Farber and Harvard Medical School.”
“This is expected to be the first of many new innovative therapies made possible by the Wyss Institute’s collaborative model of translational research that will enter human clinical trials,” said Wyss Founding Director Don Ingber, M.D., Ph.D., who is also the Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children’s Hospital, and a Professor of Bioengineering at Harvard SEAS. “It validates our approach, which strives to move technologies into the clinical space much faster than would be possible in a traditional academic environment. It’s enormously gratifying to see one of our first technologies take this giant leap forward.”
The Wyss Institute comprises a consortium of researchers, engineers, clinicians, and staff with industrial and business development experience from the Wyss Institute and nine other collaborating institutions in Greater Boston.
“It is rare to get a new technology tested in the laboratory and moved into human clinical trials so quickly,” said Dranoff, who is also a Professor of Medicine at Harvard Medical School, and Leader of the Dana-Farber/Harvard Cancer Center Program in Cancer Immunology. “We’re beyond thrilled with the momentum, and excited about its potential.”
The Latest on: Cancer Vaccine
- Anal cancer rates and deaths are climbing in the US, study sayson November 20, 2019 at 4:06 am
The study found anal cancer cases have increased significantly in people aged 50 and older. It might be because HPV vaccine guidelines are “very narrow,” Shaffer said, limiting protection for older ...
- Groundbreaking Canine Cancer Vaccine Trial Underway At UC Davison November 19, 2019 at 7:52 pm
One of the world’s top veterinary hospitals is testing out a new strategy to stop multiple types of cancer in dogs with a groundbreaking vaccine study. Cancer is the leading cause of death in dogs.
- Researchers propose a novel method to underscore the benefits of HPV vaccineon November 19, 2019 at 5:36 am
Despite these recommendations and established success of the vaccine at preventing cancer-causing HPV, just over half of those eligible are fully up-to-date on vaccination, according to an August 2019 ...
- Clinic: I'm worried about negative publicity on HPV vaccineon November 18, 2019 at 9:32 pm
Boys can also be vaccinated, boosting protection against genital warts and anal cancer. ALSO READ: HPV vaccine the answer to war on cervical cancer Western countries already have very effective HPV ...
- What if our bodies could fight cancer on their own? A local lab hopes to accomplish this.on November 18, 2019 at 4:09 pm
10News Anchor Allison Kropff shows you how a local company is testing a cancer vaccine on humans right here in Tampa Bay. Human tests are now underway since there have promising results in animals.
- Common TB vaccine associated with lower lung cancer rateson November 18, 2019 at 10:22 am
(HealthDay)—Childhood vaccination with the bacille Calmette-Guérin (BCG) vaccine is associated with a reduced risk for lung cancer, according to a study published online Sept. 25 in JAMA Network Open.
- New Study: HPV Vaccine Is Safe For Kids In Preventing Certain Cancerson November 18, 2019 at 10:08 am
Only about half of today’s adolescents are completing the HPV vaccine, which can prevent cervical and head and neck cancers. HPV is very common, with about 14 million people becoming infected with the ...
- Studies confirm HPV vaccine is safeon November 18, 2019 at 8:24 am
The HPV vaccine gives parents a chance to prevent their children from developing some types of cancer, and two new studies reaffirm what past research has found -- the vaccine is safe. The two studies ...
- Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapieson November 18, 2019 at 8:06 am
Furthermore, low-dose NanoNO reprogrammes the immunosuppressive tumour microenvironment toward an immunostimulatory phenotype, thereby improving the efficacy of cancer vaccine immunotherapy. Our ...
- Researchers find simpler, more effective cancer vaccine approachon November 14, 2019 at 5:02 am
The finding, described online in the Journal of Clinical Investigation, provides an alternative to dendritic cell cancer vaccines, which have shown promise as a way to prompt T-cells to recognize and ...
via Google News and Bing News